Merz Therapeutics

Merz Therapeutics advances innovative treatments and strategic partnerships to enhance long-term quality of life for patients with neurological and movement disorders. Clinical development programmes extend the benefits of established heritage products to broader patient populations while identifying opportunities to address unmet needs in speciality therapeutics. Collaboration with local and global patient organisations ensures alignment with patient priorities, informing research and development initiatives. Founded in 1908 by Friedrich Merz, who established the guiding principle of enquiring, “What is needed?”, the company has sustained a legacy of patient-centric innovation. Launched as a dedicated entity in 2020, Merz Therapeutics leverages this independence to focus on neurology-focused therapeutics that improve clinical outcomes and daily functioning for those impacted by chronic conditions. Current medicines address movement disorders and neurological challenges, with a robust pipeline promising further advancements. In-house research, clinician partnerships, and advocacy collaborations drive the pursuit of optimised therapies tailored to evolving patient requirements. This expertise in neurology supports sustained engagement with affected individuals and families, fostering adaptive solutions for lifelong management. Merz Therapeutics’ commitment to expansion and operational excellence underpins a strategic vision for delivering high-impact, sustainable healthcare solutions.